Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

BACKGROUND: Sustaining clinical remission is an important treatment goal in moderate-to-severe UC. This post hoc exploratory analysis assessed the long-term efficacy of vedolizumab in the subset of patients with UC in the GEMINI 1 study who were in clinical remission by week 14 after 3 induction dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Feagan, Brian G, Schreiber, Stefan, Wolf, Douglas C, Axler, Jeffrey L, Kaviya, Arpeat, James, Alexandra, Curtis, Rebecca I, Geransar, Parnia, Stallmach, Andreas, Ehehalt, Robert, Bokemeyer, Bernd, Khalid, Javaria Mona, O’Byrne, Sharon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Clinical Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499937/
https://www.ncbi.nlm.nih.gov/pubmed/30365009
http://dx.doi.org/10.1093/ibd/izy323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499937/
https://www.ncbi.nlm.nih.gov/pubmed/30365009
http://dx.doi.org/10.1093/ibd/izy323

Ejemplares similares